Biosimilar Costs Could Exceed Brands In Part D Coverage Gap
This article was originally published in The Pink Sheet Daily
Executive Summary
Biosimilars are exempt from the 50% discount manufacturers are required to provide on branded drugs for Medicare Part D beneficiaries in the coverage gap, which may result in a higher cost for the biosimilar relative to its reference drug.